ZA200606237B - Bicycloester derivative - Google Patents
Bicycloester derivativeInfo
- Publication number
- ZA200606237B ZA200606237B ZA200606237A ZA200606237A ZA200606237B ZA 200606237 B ZA200606237 B ZA 200606237B ZA 200606237 A ZA200606237 A ZA 200606237A ZA 200606237 A ZA200606237 A ZA 200606237A ZA 200606237 B ZA200606237 B ZA 200606237B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- bicycloester derivative
- bicycloester
- derivatives
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 abstract 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- AKFNKZFJBFQFAA-DIOPXHOYSA-N ethyl 4-[[2-[(2s,4s)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino]bicyclo[2.2.2]octane-1-carboxylate Chemical compound C1CC(C(=O)OCC)(CC2)CCC12NCC(=O)N1C[C@@H](F)C[C@H]1C#N AKFNKZFJBFQFAA-DIOPXHOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004029856 | 2004-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200606237B true ZA200606237B (en) | 2007-12-27 |
Family
ID=34835968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200606237A ZA200606237B (en) | 2004-02-05 | 2006-07-27 | Bicycloester derivative |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7754757B2 (de) |
| EP (1) | EP1712547B1 (de) |
| JP (1) | JP3954626B2 (de) |
| KR (1) | KR101130433B1 (de) |
| CN (2) | CN101684089A (de) |
| AT (1) | ATE537141T1 (de) |
| AU (1) | AU2005210285B2 (de) |
| BR (1) | BRPI0506622A (de) |
| CA (1) | CA2554493C (de) |
| CY (1) | CY1112550T1 (de) |
| DK (1) | DK1712547T3 (de) |
| ES (1) | ES2375625T3 (de) |
| HK (1) | HK1100511A1 (de) |
| HR (1) | HRP20120006T1 (de) |
| NO (1) | NO20063486L (de) |
| NZ (1) | NZ548440A (de) |
| PL (1) | PL1712547T3 (de) |
| PT (1) | PT1712547E (de) |
| RS (1) | RS52163B (de) |
| SI (1) | SI1712547T1 (de) |
| WO (1) | WO2005075421A1 (de) |
| ZA (1) | ZA200606237B (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1712547T3 (pl) * | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Pochodna bicykloestrowa |
| US7514571B2 (en) * | 2004-02-27 | 2009-04-07 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| US7915427B2 (en) * | 2006-03-08 | 2011-03-29 | Kyorin Pharmaceuticals Co., Ltd. | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof |
| JP2010120851A (ja) * | 2007-02-09 | 2010-06-03 | Kyorin Pharmaceut Co Ltd | 二量化シクロ誘導体 |
| US8143427B2 (en) * | 2007-03-22 | 2012-03-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
| WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用 |
| CL2008003653A1 (es) * | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| WO2010016584A1 (ja) | 2008-08-07 | 2010-02-11 | 杏林製薬株式会社 | ビシクロ[２．２．２]オクチルアミン誘導体の製造方法 |
| EP2327406A4 (de) * | 2008-08-14 | 2014-04-09 | Kyorin Seiyaku Kk | Stabilisierte pharmazeutische zusammensetzung |
| JP5906086B2 (ja) | 2008-08-15 | 2016-04-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｆａｂ関連疾患の治療に用いるためのプリン誘導体 |
| EP2332908A4 (de) * | 2008-09-16 | 2012-02-29 | Kyorin Seiyaku Kk | Verfahren zur reinigung eines aminoacetylpyrrolidincarbonitrilderivats und salz daraus |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| PL2376447T3 (pl) * | 2009-01-09 | 2018-04-30 | Orchid Pharma Limited | Inhibitory dipeptydylopeptydazy iv |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| MX2011008416A (es) | 2009-02-13 | 2011-09-08 | Boehringer Ingelheim Int | Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos. |
| US20120029032A1 (en) * | 2009-03-27 | 2012-02-02 | Kyorin Pharmaceutical Co., Ltd. | Matrix-type sustained release preparation containing basic additive |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
| BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| JP2013216580A (ja) * | 2010-08-06 | 2013-10-24 | Kyorin Pharmaceutical Co Ltd | ビシクロ［２．２．２］オクチルアミン誘導体の製造方法 |
| PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| ES2765973T3 (es) | 2013-03-14 | 2020-06-11 | Bristol Myers Squibb Co | Moduladores de GPR120 de ácido biciclo[2.2.2] |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US5965764A (en) | 1997-08-06 | 1999-10-12 | Toray Industries, Inc. | Process for producing a nitrile |
| US20030176357A1 (en) | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| WO2000056743A1 (en) | 1999-03-19 | 2000-09-28 | Anormed Inc. | Pharmaceutical compositions comprising metal complexes |
| US20040152745A1 (en) | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
| JP2003535034A (ja) | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法 |
| US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| AU2001228309A1 (en) * | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| US7064145B2 (en) | 2000-02-25 | 2006-06-20 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| TW540248B (en) | 2000-07-19 | 2003-07-01 | Koninkl Philips Electronics Nv | Method and device for generating a multiplexed MPEG signal |
| JP4101053B2 (ja) | 2000-08-10 | 2008-06-11 | 田辺三菱製薬株式会社 | プロリン誘導体及びその医薬用途 |
| US20020037829A1 (en) | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
| JP4329290B2 (ja) | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 脂肪族含窒素五員環化合物 |
| JP4329291B2 (ja) | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 含窒素五員環化合物 |
| CN1257891C (zh) | 2000-10-06 | 2006-05-31 | 田边制药株式会社 | 含氮五员环化合物 |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| DE60221098T2 (de) | 2001-02-02 | 2008-01-24 | Takeda Pharmaceutical Co. Ltd. | Kondensierte heterocyclische derivate |
| EP1406872B1 (de) | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
| EP1399433B1 (de) | 2001-06-27 | 2007-08-22 | Smithkline Beecham Corporation | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| ATE374181T1 (de) | 2001-06-27 | 2007-10-15 | Smithkline Beecham Corp | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
| AU2002316437A1 (en) | 2001-06-27 | 2003-03-03 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| ATE388951T1 (de) | 2001-07-03 | 2008-03-15 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
| US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| WO2003057144A2 (en) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| WO2003080633A1 (en) | 2002-03-25 | 2003-10-02 | Nippon Kayaku Kabushiki Kaisha | Novel $g(a)-amino-n-(diaminophosphinyl)lactam derivative |
| JP4329381B2 (ja) | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4329382B2 (ja) | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US20040106802A1 (en) | 2002-04-08 | 2004-06-03 | Torrent Pharmaceuticals Ltd. | Novel compounds and therapeutic uses thereof |
| RU2004132719A (ru) | 2002-04-08 | 2005-08-27 | Торрент Фармасьютикалз Лтд. (In) | Тиазолидин-4-карбонитрилы и их аналоги, применение указанных соединений в качестве ингибиторов дипептидилпептидаз |
| AU2003235913A1 (en) | 2002-05-09 | 2003-11-11 | Taisho Pharmaceutical Co., Ltd. | Cyanopyrrolidine derivatives |
| JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼｉｖ阻害剤 |
| HUP0202001A2 (hu) | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
| GB0214344D0 (en) | 2002-06-21 | 2002-07-31 | Givaudan Sa | New odorant Compounds |
| WO2004007446A1 (ja) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | 新規なアゼチジン誘導体又はその塩 |
| TW200401635A (en) | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
| CA2497725C (en) | 2002-09-19 | 2012-04-10 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| AU2003902260A0 (en) | 2003-05-09 | 2003-05-29 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| ES2940341T3 (es) | 2004-01-20 | 2023-05-05 | Novartis Ag | Formulación y proceso de compresión directa |
| PL1712547T3 (pl) * | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Pochodna bicykloestrowa |
| US7560569B2 (en) | 2004-02-18 | 2009-07-14 | Kyorin Pharmaceutical Co., Ltd | Bicycloamide derivative |
| US7514571B2 (en) | 2004-02-27 | 2009-04-07 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
| TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
| AR050615A1 (es) | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
| AP2007003973A0 (en) | 2004-10-12 | 2007-07-30 | Glenmark Pharmaceuticals Sa | Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation |
| JP2008019168A (ja) | 2004-10-22 | 2008-01-31 | Astellas Pharma Inc | ２−シアノ−４−フルオロピロリジン誘導体の製造法 |
| JP2006160733A (ja) | 2004-11-15 | 2006-06-22 | Taisho Pharmaceut Co Ltd | シアノフルオロピロリジン誘導体を有効成分として含有する医薬 |
| GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
| MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| US7915427B2 (en) | 2006-03-08 | 2011-03-29 | Kyorin Pharmaceuticals Co., Ltd. | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof |
| JP2010120851A (ja) | 2007-02-09 | 2010-06-03 | Kyorin Pharmaceut Co Ltd | 二量化シクロ誘導体 |
| US8143427B2 (en) | 2007-03-22 | 2012-03-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
| JP2008239543A (ja) | 2007-03-27 | 2008-10-09 | Kyorin Pharmaceut Co Ltd | ビシクロアミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 |
| JP2008290969A (ja) | 2007-05-24 | 2008-12-04 | Kyorin Pharmaceut Co Ltd | アミノアセチルピロリジン誘導体の製造方法 |
| JP2009114127A (ja) | 2007-11-07 | 2009-05-28 | Kyorin Pharmaceut Co Ltd | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
-
2005
- 2005-02-01 PL PL05704327T patent/PL1712547T3/pl unknown
- 2005-02-01 CN CN200910175524A patent/CN101684089A/zh active Pending
- 2005-02-01 AT AT05704327T patent/ATE537141T1/de active
- 2005-02-01 KR KR1020067015699A patent/KR101130433B1/ko not_active IP Right Cessation
- 2005-02-01 BR BRPI0506622-0A patent/BRPI0506622A/pt not_active IP Right Cessation
- 2005-02-01 ES ES05704327T patent/ES2375625T3/es active Active
- 2005-02-01 WO PCT/JP2005/001377 patent/WO2005075421A1/ja active Application Filing
- 2005-02-01 CA CA2554493A patent/CA2554493C/en not_active Expired - Fee Related
- 2005-02-01 EP EP05704327A patent/EP1712547B1/de active Active
- 2005-02-01 JP JP2005517671A patent/JP3954626B2/ja not_active Expired - Fee Related
- 2005-02-01 AU AU2005210285A patent/AU2005210285B2/en not_active Ceased
- 2005-02-01 PT PT05704327T patent/PT1712547E/pt unknown
- 2005-02-01 RS RS20120076A patent/RS52163B/en unknown
- 2005-02-01 SI SI200531480T patent/SI1712547T1/sl unknown
- 2005-02-01 US US10/588,660 patent/US7754757B2/en not_active Expired - Fee Related
- 2005-02-01 CN CN2005800041918A patent/CN1918119B/zh not_active Expired - Fee Related
- 2005-02-01 DK DK05704327.5T patent/DK1712547T3/da active
- 2005-02-01 NZ NZ548440A patent/NZ548440A/xx not_active IP Right Cessation
-
2006
- 2006-07-27 ZA ZA200606237A patent/ZA200606237B/xx unknown
- 2006-07-31 NO NO20063486A patent/NO20063486L/no not_active Application Discontinuation
-
2007
- 2007-05-30 HK HK07105747.8A patent/HK1100511A1/xx not_active IP Right Cessation
-
2009
- 2009-12-08 US US12/654,018 patent/US8053465B2/en not_active Expired - Fee Related
-
2011
- 2011-12-21 CY CY20111101277T patent/CY1112550T1/el unknown
-
2012
- 2012-01-03 HR HR20120006T patent/HRP20120006T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0506622A (pt) | 2007-05-02 |
| AU2005210285B2 (en) | 2008-01-24 |
| HK1100511A1 (en) | 2007-09-21 |
| JP3954626B2 (ja) | 2007-08-08 |
| NO20063486L (no) | 2006-08-29 |
| CN1918119B (zh) | 2011-08-31 |
| CA2554493A1 (en) | 2005-08-18 |
| WO2005075421A1 (ja) | 2005-08-18 |
| PT1712547E (pt) | 2012-03-06 |
| EP1712547A1 (de) | 2006-10-18 |
| US20080146818A1 (en) | 2008-06-19 |
| EP1712547A4 (de) | 2007-09-26 |
| NZ548440A (en) | 2009-07-31 |
| EP1712547B1 (de) | 2011-12-14 |
| DK1712547T3 (da) | 2012-03-19 |
| HRP20120006T1 (hr) | 2012-01-31 |
| US8053465B2 (en) | 2011-11-08 |
| CN1918119A (zh) | 2007-02-21 |
| SI1712547T1 (sl) | 2012-04-30 |
| AU2005210285A1 (en) | 2005-08-18 |
| KR101130433B1 (ko) | 2012-03-27 |
| CN101684089A (zh) | 2010-03-31 |
| CY1112550T1 (el) | 2016-02-10 |
| PL1712547T3 (pl) | 2012-04-30 |
| US7754757B2 (en) | 2010-07-13 |
| ES2375625T3 (es) | 2012-03-02 |
| KR20060130641A (ko) | 2006-12-19 |
| RS52163B (en) | 2012-08-31 |
| CA2554493C (en) | 2012-06-26 |
| ATE537141T1 (de) | 2011-12-15 |
| US20100093825A1 (en) | 2010-04-15 |
| JPWO2005075421A1 (ja) | 2007-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200606237B (en) | Bicycloester derivative | |
| MX2007006397A (es) | Derivados de tetrahidropirano. | |
| ATE324371T1 (de) | N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten | |
| TW200716589A (en) | Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]-oxepino [4,5-c] pyrrole | |
| NO20020725L (no) | Celleadhesjonsinhibitorer | |
| IL190643A0 (en) | Novel dihydropseudoerythromycin derivatives | |
| UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
| EP2269608A3 (de) | Pharmazeutische Zusammensetzungen welche Monoamin-Aufnahme-Neurotrransmitter-Reuptake-Inhibitoren und Acetylcholinesterase Inhibitoren enthalten | |
| WO2008096841A1 (ja) | 二量化シクロ誘導体 | |
| TW200500339A (en) | Pyrrolidine derivatives, and process for the preparation | |
| DE60027144D1 (de) | Hydroxamsäure-derivate | |
| WO2002067865A3 (en) | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | |
| MX2009000767A (es) | Sintesis de (2s,5r)-5-etinil-1-{n-(4-metil-1-(4-carboxi-piridin-2- il)piperidin-4-il)glicil}pirrolidina-2-carbonitrilo. | |
| MXPA05006889A (es) | Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos. | |
| TW200510370A (en) | Urea derivatives | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| WO2001004112A3 (de) | Benzofuranderivate | |
| ATE491709T1 (de) | Pyrrolidinohydrochinazoline | |
| AU2003272967A1 (en) | Processes for producing optically active n-(2,3-epoxypropan-1-yl)phthalimide | |
| WO2004099129A3 (en) | Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same | |
| RS20050063A (en) | Pyrrolidine derivatives as tryptase inhibitors |